Yahoo News: Cancer

BRCA Gene Mutations Linked to Salivary Gland Cancer

Mon, 09/29/2014 - 14:41
The genetic mutations that put people at high risk for breast cancer may also be linked with an increased risk of salivary gland cancer, a new study suggests. Researchers analyzed information from 187 people with breast cancer who had mutations in the BRAC1 and BRAC2 genes — which are linked with a high risk of breast and ovarian cancer. The researchers also examined several generations of ...

Seattle Genetics, Takeda's cancer drug meets main goal in trial

Mon, 09/29/2014 - 11:46
(Reuters) - Seattle Genetics Inc and Takeda Pharmaceutical Co Ltd said their approved cancer drug was successfully used as a consolidation therapy in a late-stage trial for patients with a type of lymphatic cancer. Consolidation therapy is given to cancer patients who have undergone initial therapy and kills any cancer cells that may be left in the body. ...

Merck immunotherapy drug shows promise in bladder cancer

Mon, 09/29/2014 - 09:19
MADRID (Reuters) - Merck & Co's new immune system drug Keytruda has produced encouraging results in early tests against bladder cancer, according to a company-sponsored study, prompting the firm to prepare a clinical trial later this year. Keytruda is the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, but it also has potential in a ...

Roche breast cancer drug 'helps patients live longer'

Sun, 09/28/2014 - 22:48
Geneva (AFP) - A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.

Gain from adding Roche's Avastin to immune drug unclear

Sun, 09/28/2014 - 15:57
By Ben Hirschler MADRID (Reuters) - It is too early to say whether combining Roche's best-selling Avastin cancer drug with the company's experimental immune-boosting medicine MPDL3280A gives a better outcome in fighting tumors. That is the verdict of experts following a presentation of a small clinical study assessing the combination in patients with a variety of solid tumors. ...

Failed cancer vaccines might live again with new immune drugs

Sun, 09/28/2014 - 09:31
By Ben Hirschler MADRID (Reuters) - Using vaccines to fight cancer is a field littered with failures but experts believe it is possible the approach could get a new lease of life if such shots are combined with a new class of drugs called checkpoint inhibitors. Unlike traditional preventative vaccines, therapeutic cancer vaccines are designed for people with established disease and are supposed ...

Merck drug extends immune system fight to stomach cancer

Sun, 09/28/2014 - 07:51
By Ben Hirschler MADRID (Reuters) - Merck & Co's drug Keytruda, the first in a new wave of immune-boosting medicines to be approved for treating melanomas in the United States, also has potential in stomach cancer, new research shows. Early clinical trial results reported on Sunday mean that gastric, or stomach cancer can be added to a growing list of tumor types where so-called immunotherapy ...

Roche breast cancer drug shows 'unprecedented' survival benefit

Sun, 09/28/2014 - 07:15
By Ben Hirschler MADRID (Reuters) - A new breast cancer drug from Roche has shown "unprecedented" survival benefits in a clinical trial, boosting prospects for its widespread use in women with an aggressive form of the disease. Patients with a type of breast cancer known as HER-2 positive, which makes up about a quarter of all breast cancers, who were given Perjeta on top of older medicine ...

No benefit from continued use of AstraZeneca's Iressa drug

Sun, 09/28/2014 - 07:13
By Ben Hirschler MADRID (Reuters) - Continuing to give AstraZeneca's drug Iressa plus chemotherapy to lung cancer patents whose disease has worsened after previously taking the medicine on its own does not provide any benefit. Some doctors had hoped that extending the use of Iressa in combination with chemotherapy would help to keep cancers at bay, even when tumor cells had started to develop ...

AstraZeneca sticks to second-half 2015 timetable for new lung cancer pill

Sat, 09/27/2014 - 14:20
MADRID (Reuters) - AstraZeneca said on Saturday it expected to file a new lung cancer pill for U.S. regulatory approval in the second half of 2015, potentially disappointing some investors who had hoped the drug might be ready faster. Analysts at Citi said in a research note this week they believed AZD9291 could be submitted as early as the first quarter of 2015, putting AstraZeneca ahead in a ...

Early data promising for AstraZeneca cancer drug combination

Sat, 09/27/2014 - 11:48
By Ben Hirschler MADRID (Reuters) - Early results for a closely watched cancer drug combination from AstraZeneca that boosts the immune system show the cocktail is promising, though limited patient numbers mean the data is far from conclusive. The British drugmaker, which fended off a $118 billion (72.64 billion pound) takeover bid from Pfizer in May in part by talking up its cancer drug ...

Pfizer drug effective in patients with rare lung cancer: study

Sat, 09/27/2014 - 10:51
By Bill Berkrot (Reuters) - Pfizer Inc's Xalkori, which treats lung cancer patients with a specific gene mutation, proved effective in shrinking tumors in those with an even rarer form of the disease, according to data presented at a medical meeting on Saturday. In the study of 50 non-small cell lung cancer patients with a rearrangement of the ROS1 gene, Xalkori treatment led to significant ...

Texas jury finds cancer doctor guilty of poisoning lover's coffee

Fri, 09/26/2014 - 16:58
By Amanda Orr HOUSTON (Reuters) - A Texas jury on Friday found a Houston breast cancer specialist guilty of spiking the coffee of her lover, a fellow cancer doctor, with a compound used in antifreeze. Dr. Ana Maria Gonzalez-Angulo, 43, an oncologist at the University of Texas MD Anderson Cancer Center, was accused of lacing the coffee of Dr. George Blumenschein, 50, with ethylene glycol in 2013 ...

Texas cancer doctor convicted of poisoning lover

Fri, 09/26/2014 - 16:33
HOUSTON (AP) — A cancer researcher in Texas was convicted Friday of aggravated assault for poisoning her colleague, who was also her lover, by lacing his coffee with a sweet-tasting chemical found in antifreeze.

3 from FDNY who worked at ground zero die in 1 day

Thu, 09/25/2014 - 17:34
NEW YORK (AP) — Three retired firefighters who worked at ground zero have died on the same day from cancer, an illness that many fear might be connected to toxic World Trade Center dust released on Sept. 11, fire officials said Thursday.

Roche says Avastin prolongs life in breast cancer study

Thu, 09/25/2014 - 06:34
FRANKFURT (Reuters) - Swiss drugmaker Roche said its cancer drug Avastin helped women with a common form of breast cancer live longer without their disease worsening, when used in combination with chemotherapy drug Xeloda. Results of a Phase III study involving 185 patients with HER2-negative metastatic breast cancer found those treated with both drugs saw an almost threefold improvement in how ...

Increasing Skirt Size Linked to Breast Cancer Risk

Wed, 09/24/2014 - 23:22
Women who gain weight around the waist and whose skirt sizes therefore increase between their 20s and 60s may be at higher risk of breast cancer after menopause, a new study from the United Kingdom suggests. The study, which looked at more than 92,000 women postmenopausal women over age 50, found that going up a skirt size over a period of 10 years after age 25 was linked with a 33 percent ...

Adaptimmune raises $104 million to develop immune-system cancer drugs

Wed, 09/24/2014 - 23:03
LONDON (Reuters) - British biotechnology company Adaptimmune has raised $104 million in venture capital to fund its work in developing a new range of drugs based on immune-system cells. The Oxford-based private company plans to use the money to advance its programs to clinical trials against multiple types of cancer, it said on Thursday. The oversubscribed funding round was one of the past ...

Jurors deliberating in poisoned doctor trial

Wed, 09/24/2014 - 22:52
HOUSTON (AP) — A Texas cancer researcher accused of poisoning a colleague who was also her lover was described by prosecutors on Wednesday as a devious and manipulative person who took extreme action when the man she'd become obsessed with rejected her.

Joan Lunden's Brave & Bald Debut After Cancer Battle

Wed, 09/24/2014 - 20:53
Joan Lunden is not shying away from the public as she battles cancer. In fact, she's facing it head on with a bald and beautiful People magazine cover.